$0
0 item(s) in the shopping cart

Improve a company’s sustainability performance
By using the world’s most comprehensive CSR metrics database and analysis tools

BioMarin Pharmaceutical Inc. CSR Ratings

47
CSR Rating Compared To All Companies
?
Community
50
Employees
52
Environment
41
Governance
45
Low
0-29
30-39
40-49
50-59
60-79
80-100
High
?
CSR Rating History
This company vs 16,133 companies
The average for the 295 companies in the Biotechnology industry
?

0 Special Issues

Affect This Company

?
15
Active Sources
18 Total Sources
?
Share This Summary

BioMarin is a multinational biopharmaceutical company that specializes in providing first-to-market therapeutics to patients with rare genetic diseases. The company's product portfolio comprises three approved products and multiple clinical and preclinical product candidates. Approved products include Naglazyme for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; and Kuvan Tablets, a product for the treatment of phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany. The company was established in 1997 and employs a staff of 675 worldwide.

Ticker: BMRN
ISIN: US09061G1013
Address:

105 Digital Drive

  Novato, CA, 94949, USA
Website: BioMarin Pharmaceutical Inc.
Phone #: 415-5066700
CSR Web Area: Subscribers Only ?
Industry: Biotechnology
PRIORITIES
Community
2.6
Employees
2.8
Environment
3.7
Governance
2.9
Edit your profiles
SWITCH PROFILE
Data Date
January 01, 2016
0 SPECIAL ISSUES SELECTED
CSRHub Subscribers Get Much More
CSRHub subscribers gain unparalleled and direct access to over 94 million data items, our easy-to-use suite of benchmarking and comparison tools, as well as our popular custom excel dashboards.
Access CSRHub's Premium Features